6097-31-0 Usage
General Description
2-(3,4-dichlorophenyl)-3-oxobutanenitrile, also known as 2-(3,4-dichlorophenyl)-3-oxo-n-butyronitrile, is a chemical compound with the molecular formula C10H6Cl2N2O. It is a yellow to light brown crystalline powder, and is used as a precursor in the synthesis of pharmaceuticals and agrochemicals. It is also a key intermediate in the production of certain dyes and pigments. The compound is considered to have low toxicity, with limited evidence of harmful effects on human health. However, it is important to handle and use this chemical with care, following proper safety precautions and guidelines to prevent any potential hazards.
Check Digit Verification of cas no
The CAS Registry Mumber 6097-31-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,0,9 and 7 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 6097-31:
(6*6)+(5*0)+(4*9)+(3*7)+(2*3)+(1*1)=100
100 % 10 = 0
So 6097-31-0 is a valid CAS Registry Number.
InChI:InChI=1/C10H7Cl2NO/c1-6(14)8(5-13)7-2-3-9(11)10(12)4-7/h2-4,8H,1H3
6097-31-0Relevant articles and documents
N -Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK
Pippione, Agnese C.,Sainas, Stefano,Federico, Antonella,Lupino, Elisa,Piccinini, Marco,Kubbutat, Michael,Contreras, Jean-Marie,Morice, Christophe,Barge, Alessandro,Ducime, Alex,Boschi, Donatella,Al-Karadaghi, Salam,Lolli, Marco L.
supporting information, p. 963 - 968 (2018/06/27)
NF-κB-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low μM selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-κB pathway in tumour cells, confirming its selective inhibitory profile.
